Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 19/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | MC5R | P33032 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25586770 | 0.89 | MC4R (0.63) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL25586768 | 0.89 | MC4R (0.63) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL25588019 | 0.88 | MC4R (0.44) | MC4RKCNH2MC5RMC3RFFAR1 | |
| SCHEMBL25588046 | 0.86 | MC4R (0.48) | MC4RKCNH2MC5RMC3RFFAR1 | |
| SCHEMBL25586604 | 0.86 | MC4R (0.51) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL25588184 | 0.84 | MC4R (0.53) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL25587945 | 0.83 | MC4R (0.58) | MC4RKCNH2MC5RMC3R | |
| SCHEMBL25588031 | 0.83 | MC4R (0.44) | MC4R | |
| SCHEMBL24094652 | 0.81 | MC4R (0.42) | MC4RKCNH2MC5RMC3RFFAR1 | |
| SCHEMBL25587968 | 0.80 | MC4R (0.55) | MC4RKCNH2MC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | PFIZER INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | PFIZER INC. (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174532-A1 | METHODS FOR ANTAGONIZING A MELANOCORTIN 4 RECEPTOR | MC4R, MC2R, NPY4R | MC4R 1/4885KCNH2 3858/4885MC5R 4/4885 |
| US-11643412-B2 | Melanocortin 4 receptor antagonists and uses thereof | MC4R, MC3R, MC5R | MC4R 1/4885KCNH2 3177/4885MC5R 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.